Document ZDgQdpadVQy5NXk1M8377rb8

Corporate Health Physics Corporate IndustrialHygiene & Ergonomics Corporate Occupational Medicine Corporate Toxicology 3M Medical Department 3M Center,Building220-2E-02 PO Box 33220 - St.Paul,MN 55133-3220 651 733 1110 May 3, 2000 Facsimile Dr. JenniferSeed 202-260-1279 USEPA Headquarters ArielRios Building 1200 Pennsylvania Avenue, N. W. Washington, DC 20460 Re: Serum measurements forArgus Studies418-013 (throughlactationa)nd 418-015 (during gesatation) Dear Jennifer: I am includingin thisfax the two setsof senan perfluorooctanesulfonatmeeasurements from the following two studies: 1. Oral (Gavage) Pharmacokinetic Recovery Study of PFOS in Rats,Argus LaboratoriesProtocolNo. 418-015, 3M Reference No. T-6295.14, Advanced BioanalyticalServiceiStudy No. FACT- TOX-1 11. 2. Oral (Gavage) Pharmacokinetic Study of PFOS in Rats,Argus LaboratoriesProtocolNo. 418-013, 3M Reference No. T-6295.12, Advanced Bioanalylkat Servkes Study No. FACT-TOX-110. The informnationwhich I have includedrelatesto the analyticasltudiesindicatedabove inbold itaucs. Included are pages 10-19 of FACT-TOX-1 II and pages 13-23 of FACT-TOX-1 10. 3M has previously sentthe in-lifreeportsand protocolsforthe analyticalphase to the attentionof Dr. Hernandez. I would be happy to meet with you and your EPA colleaguesand consultantsto provide whatever assistanceyou may desirein understandingthe toxicologicalinformationthatisbeing provided. Please contactme with any questionsor ifyou would liketo arrange a meeting. Sincerely, John L. Butenhoff,Ph.D., CIH, DABT Senior Laboratory Manager Corporate Toxicology (651) 733-1962